Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Value in Oncology
NCCN Panel Debates Cancer Care in Value-Based Healthcare Models
By
Wayne Kuznar
NCCN Annual Conference
,
Value in Oncology
Web Exclusives
Experts at this roundtable discussion addressed high patient costs, achieving greater value in oncology care, and the desire for access to comparative data.
Read Article
FDA Implements New Steps to Encourage Generic Drug Competition, Expand Patients’ Access to Inexpensive Medicines
By
Eileen Koutnik-Fotopoulos
Value in Oncology
Web Exclusives
In a January 3, 2018, statement from FDA Commissioner Scott Gottlieb, MD, the FDA announced new steps to promote generic drug competition as a way to expand potential access to inexpensive medicines, which would be especially helpful for patients with cancer. These new steps are a part of the FDA’s ongoing implementation of the Drug Competition Action Plan.
Read Article
Rapid Adoption of Oncology Drugs Improves Survival
By
Chase Doyle
Value in Oncology
December 2017, Vol 8, No 5
Innovation takes time, especially when it comes to cancer research. However, delays in the adoption of novel oncology treatments can have a significant impact on patient health, reported Jason Shafrin, PhD, Director of Healthcare Quality and Value-Based Research Methods, and Senior Research Economist, Precision Health Economics, Los Angeles, CA, who presented the results of a geographic-based analysis of claims data at the 2017 Cancer Survivorship Symposium.
Read Article
Identifying Correct Molecular Target Essential for Treating Non–Small-Cell Lung Cancer
By
Wayne Kuznar
Value in Oncology
December 2017, Vol 8, No 5
Orlando, FL—Non–small-cell lung cancer (NSCLC) comprises several different subtypes, necessitating broad molecular panel testing to understand the correct diagnosis and the appropriate treatment, said Wallace Akerley, MD, Senior Director, Community Oncology Research, Huntsman Cancer Institute, University of Utah, Salt Lake City, at the 2017 National Comprehensive Cancer Network (NCCN) annual conference.
Read Article
ASCO Annual Report 2017: Immunotherapy 2.0 Advance of the Year
By
Eileen Koutnik-Fotopoulos
Value in Oncology
June 2017, Vol 8, No 3
Advances in immunotherapy are benefiting increasing numbers of patients living with cancer. Since 2011, the FDA approved 15 immunotherapies in oncology, including 5 immunotherapy drugs in 2016. This surge of progress using cancer immunotherapy has led the American Society of Clinical Oncology (ASCO) to name “Immunotherapy 2.0” as its cancer advance of the year for a second year in a row.
Read Article
Clinical Pathways Cut Costs of Care in Non–Small-Cell Lung Cancer While Preserving Survival Rates
By
Wayne Kuznar
Value in Oncology
June 2017, Vol 8, No 3
Implementing clinical pathways for the management of patients with metastatic non–small-cell lung cancer (NSCLC) led to a dramatic reduction in the total cost of care, while maintaining clinical outcomes, according to a study of 370 patients with NSCLC conducted at Dana-Farber Cancer Institute in Boston.
Read Article
Comparing the Current Value Frameworks in Oncology
By
Meg Barbor, MPH
Value in Oncology
April 2017, Vol 8, No 2
Chicago, IL—Escalating drug prices have put value frameworks in the spotlight, and the identification of the key questions and the audience addressed in each value framework is vital to understanding the value landscape, said Kasia Shields, PharmD, MBA, BCOP, BCPS, Director, Medical Communications, Xcenda/AmerisourceBergen, at the 2016 Hematology/Oncology Pharmacy Association Oncology Pharmacy Practice Management Program.
Read Article
How Washington Is Shaping a New Healthcare Reform
By
Gail Thompson
Value in Oncology
April 2017, Vol 8, No 2
Former Senator Bill Frist, MD, opened the 2017 Cancer Center Business Summit in Las Vegas, NV, in early February, with a smile and a warning that we are in unfamiliar territory as the new Congress and the new administration move into 2017, territory that may occur only 2 or 3 times in a century. He said that, “For the first time since 1929, the GOP [the Republican Party] controls Congress, the White House, most governorships and state houses, as well as the Supreme Court.”
Read Article
Leveraging Financial Advocates to Improve Patient Care
By
Meg Barbor, MPH
Value in Oncology
April 2017, Vol 8, No 2
St Louis, MO—Financial counselors can help patients find assistance with the often-prohibitive costs of cancer treatment. According to Jordan Karwedsky, a financial counselor at HSHS St Vincent Regional Cancer Center and Green Bay Oncology, Green Bay, WI, patients at these organizations saved more than $1 million on intravenous and oral chemotherapy in 2015 through copay assistance.
Read Article
Shifting Targets for Providers, Payers, and Patients with Cancer: Perspectives in Healthcare Reform
By
Gail Thompson
Value in Oncology
April 2017, Vol 8, No 2
Las Vegas, NV—A panel discussion at the 2017 Cancer Center Business Summit revealed continuing gaps in the evolution of healthcare reform among providers, payers, and patients with cancer. Michael Kolodziej, MD, National Medical Director, Managed Care Strategy, Flatiron Health, New York, NY—an oncologist with experience on the provider and the payer sides—moderated the panel discussion, which offered perspectives from the trenches on healthcare reform.
Read Article
Page 1 of 7
1
2
3
4
5
6
7
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma